UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

S123: SAFETY AND EFFICACY OF EARLY-START DEFERIPRONE IN INFANTS AND YOUNG CHILDREN WITH BETA-THALASSEMIA (START STUDY)

HemaSphere, 2022-01, Vol.6 (Suppl), p.12-13

2022

Volltextzugriff (PDF)

Effect of hypoxia on cytochrome P450 activity and expression

Current drug metabolism, 2004-06, Vol.5 (3), p.257-271

2004

Volltextzugriff (PDF)

P1558: EARLY‐START DEFERIPRONE IN INFANTS/YOUNG CHILDREN WITH TRANSFUSION‐DEPENDENT BETA THALASSEMIA: EVIDENCE FOR IRON SHUTTLING TO TRANSFERRIN—RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED TRIAL (START)

HemaSphere, 2022-06, Vol.6 (Suppl), p.1439-1440

2022

Volltextzugriff (PDF)

PB2231: RATIONALE FOR THE USE OF COMBINATION CHELATION THERAPY IN PATIENTS WITH THALASSEMIA SYNDROMES OR SICKLE CELL ANEMIA: A SYSTEMATIC LITERATURE REVIEW

HemaSphere, 2022-06, Vol.6 (Suppl), p.2101-2102

2022

Volltextzugriff (PDF)

P1511: EFFICACY AND SAFETY OF COMBINATION IRON CHELATION THERAPY WITH DEFERIPRONE AND DEFERASIROX IN PATIENTS WITH Β‐THALASSEMIA MAJOR: A SYSTEMATIC LITERATURE REVIEW

HemaSphere, 2022-06, Vol.6 (Suppl), p.1392-1393

2022

Volltextzugriff (PDF)

Normative Data for the Pyramids and Palm Trees Test in the Quebec-French Population

Archives of clinical neuropsychology, 2010-05, Vol.25 (3), p.212-217

2010

Volltextzugriff (PDF)

S115: LONG-TERM EFFICACY AND SAFETY OF DEFERIPRONE FOR PATIENTS WITH SICKLE CELL DISEASE OR OTHER ANEMIAS

HemaSphere, 2022-01, Vol.6 (Suppl), p.8-8

2022

Volltextzugriff (PDF)

S120: RANDOMIZED CONTROLLED TRIAL OF THE EFFICACY AND SAFETY OF DEFERIPRONE: SUBGROUP ANALYSIS OF PEDIATRIC PATIENTS IN IRON‐OVERLOADED PATIENTS WITH SICKLE CELL DISEASE AND OTHER ANEMIAS

HemaSphere, 2022-01, Vol.6 (Suppl), p.10-11

2022

Volltextzugriff (PDF)

Safety, tolerability, and pharmacokinetics of once-daily trazodone extended-release caplets in healthy subjects

International journal of clinical pharmacology and therapeutics, 2011-12, Vol.49 (12), p.730-743

2011

Volltextzugriff (PDF)

Effects of Labor on Placental Expression of Superoxide Dismutases in Preeclampsia

Placenta (Eastbourne), 2010-05, Vol.31 (5), p.392-400

2010

Volltextzugriff (PDF)

Analysis of the Risk of Infection Stratified By Absolute Neutrophil Counts during Deferiprone-Associated Severe Neutropenia or Agranulocytosis

BLOOD, 2023-11, Vol.142 (Supplement 1), p.2501-2501

2023

Volltextzugriff (PDF)

S115: LONG‐TERM EFFICACY AND SAFETY OF DEFERIPRONE FOR PATIENTS WITH SICKLE CELL DISEASE OR OTHER ANEMIAS

HemaSphere, 2022-01, Vol.6, p.8-8

2022

Volltextzugriff (PDF)

Rates of severe neutropenia and infection risk in patients treated with deferiprone: 28 years of data

Blood advances, 2024-11, Vol.8 (21), p.5641-5649

2024

Volltextzugriff (PDF)

Pomelo juice but not cranberry juice affects the disposition of cyclosporine in humans

Clinical pharmacology and therapeutics, 2005-02, Vol.77 (2), p.P80-P80

2005

Volltextzugriff (PDF)

Pomelo juice, but not cranberry juice, affects the pharmacokinetics of cyclosporine in humans

Clinical pharmacology and therapeutics, 2006-03, Vol.79 (3), p.255-262

2006

Volltextzugriff (PDF)

S123: SAFETY AND EFFICACY OF EARLY‐START DEFERIPRONE IN INFANTS AND YOUNG CHILDREN WITH BETA‐THALASSEMIA (START STUDY)

HemaSphere, 2022-01, Vol.6, p.12-13

2022

Volltextzugriff (PDF)

RANDOMIZED CONTROLLED TRIAL OF THE EFFICACY AND SAFETY OF DEFERIPRONE: SUBGROUP ANALYSIS OF PEDIATRIC PATIENTS IN IRON-OVERLOADED PATIENTS WITH SICKLE CELL DISEASE AND OTHER ANEMIAS

Hematology, Transfusion and Cell Therapy, 2022-10, Vol.44, p.S338-S339

2022

Volltextzugriff (PDF)

Hypoxia‐inducible factor‐1 and activator protein‐1 modulate the upregulation of CYP3A6 induced by hypoxia

British journal of pharmacology, 2003-11, Vol.140 (6), p.1146-1154

2003

Volltextzugriff (PDF)

5‐Hydroxytryptamine is biotransformed by CYP2C9, 2C19 and 2B6 to hydroxylamine, which is converted into nitric oxide

British journal of pharmacology, 2004-02, Vol.141 (3), p.407-414

2004

Volltextzugriff (PDF)

Hypoxia‐induced down‐regulation of CYP1A1/1A2 and up‐regulation of CYP3A6 involves serum mediators

British journal of pharmacology, 2002-11, Vol.137 (6), p.881-891

2002

Volltextzugriff (PDF)

Modulation of CYP1A2 and CYP3A6 catalytic activities by serum from rabbits with a turpentine-induced inflammatory reaction and interleukin 6

Drug metabolism and disposition, 2006-01, Vol.34 (1), p.27

2006

Volltextzugriff (PDF)

The 21-aminosteroid U74389G prevents the down-regulation and decrease in activity of CYP1A1, 1A2 and 3A6 induced by an inflammatory reaction

Biochemical pharmacology, 2006-01, Vol.71 (3), p.366-376

2006

Volltextzugriff (PDF)

Signal transduction pathways implicated in the decrease in CYP1A1, 1A2 and 3A6 activity produced by serum from rabbits and humans with an inflammatory reaction

Biochemical pharmacology, 2004-08, Vol.68 (3), p.573-582

2004

Volltextzugriff (PDF)

Cytochrome P450 down-regulation by serum from humans with a viral infection and from rabbits with an inflammatory reaction

Drug metabolism and disposition, 2001-07, Vol.29 (7), p.1007

2001

Volltextzugriff (PDF)

1 – 25 von 135

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(92)
Mit Volltextzugriff
(103)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(49)
Life Sciences & Biomedicine
(40)
Humans
(29)
Male
(19)
Animals
(15)
Female
(13)
Biological And Medical Sciences
(12)
Pharmacology & Pharmacy
(11)
Adult
(10)
Rabbits
(9)
Medical Sciences
(8)
Technology
(7)
Amyotrophic Lateral Sclerosis
(6)
Engineering
(6)
Middle Aged
(6)
Proteins
(6)
Adolescent
(5)
Aryl Hydrocarbon Hydroxylases - Metabolism
(5)
Biomarkers
(5)
Chemical Engineering
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

S123: SAFETY AND EFFICACY OF EARLY-START DEFERIPRONE IN INFANTS AND YOUNG CHILDREN WITH BETA-THALASSEMIA (START STUDY)

Effect of hypoxia on cytochrome P450 activity and expression

P1558: EARLY‐START DEFERIPRONE IN INFANTS/YOUNG CHILDREN WITH TRANSFUSION‐DEPENDENT BETA THALASSEMIA: EVIDENCE FOR IRON SHUTTLING TO TRANSFERRIN—RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED TRIAL (START)

PB2231: RATIONALE FOR THE USE OF COMBINATION CHELATION THERAPY IN PATIENTS WITH THALASSEMIA SYNDROMES OR SICKLE CELL ANEMIA: A SYSTEMATIC LITERATURE REVIEW

P1511: EFFICACY AND SAFETY OF COMBINATION IRON CHELATION THERAPY WITH DEFERIPRONE AND DEFERASIROX IN PATIENTS WITH Β‐THALASSEMIA MAJOR: A SYSTEMATIC LITERATURE REVIEW

Normative Data for the Pyramids and Palm Trees Test in the Quebec-French Population

S115: LONG-TERM EFFICACY AND SAFETY OF DEFERIPRONE FOR PATIENTS WITH SICKLE CELL DISEASE OR OTHER ANEMIAS

S120: RANDOMIZED CONTROLLED TRIAL OF THE EFFICACY AND SAFETY OF DEFERIPRONE: SUBGROUP ANALYSIS OF PEDIATRIC PATIENTS IN IRON‐OVERLOADED PATIENTS WITH SICKLE CELL DISEASE AND OTHER ANEMIAS

Safety, tolerability, and pharmacokinetics of once-daily trazodone extended-release caplets in healthy subjects

Effects of Labor on Placental Expression of Superoxide Dismutases in Preeclampsia

Analysis of the Risk of Infection Stratified By Absolute Neutrophil Counts during Deferiprone-Associated Severe Neutropenia or Agranulocytosis

S115: LONG‐TERM EFFICACY AND SAFETY OF DEFERIPRONE FOR PATIENTS WITH SICKLE CELL DISEASE OR OTHER ANEMIAS

Rates of severe neutropenia and infection risk in patients treated with deferiprone: 28 years of data

Pomelo juice but not cranberry juice affects the disposition of cyclosporine in humans

Pomelo juice, but not cranberry juice, affects the pharmacokinetics of cyclosporine in humans

S123: SAFETY AND EFFICACY OF EARLY‐START DEFERIPRONE IN INFANTS AND YOUNG CHILDREN WITH BETA‐THALASSEMIA (START STUDY)

RANDOMIZED CONTROLLED TRIAL OF THE EFFICACY AND SAFETY OF DEFERIPRONE: SUBGROUP ANALYSIS OF PEDIATRIC PATIENTS IN IRON-OVERLOADED PATIENTS WITH SICKLE CELL DISEASE AND OTHER ANEMIAS

Hypoxia‐inducible factor‐1 and activator protein‐1 modulate the upregulation of CYP3A6 induced by hypoxia

5‐Hydroxytryptamine is biotransformed by CYP2C9, 2C19 and 2B6 to hydroxylamine, which is converted into nitric oxide

Hypoxia‐induced down‐regulation of CYP1A1/1A2 and up‐regulation of CYP3A6 involves serum mediators

Modulation of CYP1A2 and CYP3A6 catalytic activities by serum from rabbits with a turpentine-induced inflammatory reaction and interleukin 6

The 21-aminosteroid U74389G prevents the down-regulation and decrease in activity of CYP1A1, 1A2 and 3A6 induced by an inflammatory reaction

Signal transduction pathways implicated in the decrease in CYP1A1, 1A2 and 3A6 activity produced by serum from rabbits and humans with an inflammatory reaction

Justice sociale ou efficience : Exploration de la pratique réflexive chez les diplômées en criminologie

Cytochrome P450 down-regulation by serum from humans with a viral infection and from rabbits with an inflammatory reaction

Suchergebnisse filtern